CIK: 0001388325 · Show all filings
Period: Q4 2015 (← Previous) (Next →)
Filing Date: Feb 16, 2016
Total Value ($000): $1,040,415 (99.5% shares, 0.5% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | OPHTHOTECH CORP | 4,910,487 | $385,621 | 37.1% | $32.35 | — | COM | 683745103 |
| VTI | VANGUARD INDEX FDS | 2,979,100 | $310,720 | 29.9% | $57.39 | — | TOTAL STK MKT | 922908769 |
| INGN | INOGEN INC | 3,549,320 | $142,292 | 13.7% | $17.78 | +137.8% | COM | 45780L104 |
| VGK | VANGUARD INTL EQUITY INDEX F | 2,101,000 | $104,798 | 10.1% | $45.01 | — | FTSE EUROPE ETF | 922042874 |
| — | COLUCID PHARMACEUTICALS INC | 3,056,563 | $25,583 | 2.5% | $8.90 | — | COM | 19716T101 |
| — | TOBIRA THERAPEUTICS INC | 2,471,405 | $24,838 | 2.4% | $17.25 | — | COM | 88883P101 |
| PEN | PENUMBRA, INC. | 236,144 | $12,707 | 1.2% | $43.14 | +5.0% | COM | 70975L107 |
| — | NABRIVA THERAPEUTICS AG | 874,985 | $8,417 | 0.8% | $9.50 | — | COM | 62957M104 |
| — | INVUITY INC | 925,000 | $8,158 | 0.8% | $8.82 | — | COM | 46187J205 |
| — | HTG MOLECULAR DIAGNOSTICS INC | 1,280,185 | $5,582 | 0.5% | $11.15 | — | COM | 40434H104 |
| — | WRIGHT MEDICAL GROUP | 4,622,032 | $4,714 | 0.5% | $2.50 | — | CONTINGENT VALUE RIGHTS | 98235T115 |
| — | TOKAI PHARMACEUTICALS INC | 470,946 | $4,107 | 0.4% | $14.41 | — | COM | 88907J107 |
| GKOS | GLAUKOS CORP | 75,000 | $1,852 | 0.2% | $29.05 | -21.0% | COM | 377322102 |
| XENE | XENON PHARMACEUTICALS INC | 127,563 | $1,026 | 0.1% | $14.68 | -41.6% | COM | 98420N105 |